Partner Headlines - ARNA

  1. Sportsman's Warehouse, Bob Evans, Peabody Energy Lead Tuesday's ...

    Benzinga
  2. 5 New Biotech Developments Worth Watching

    Benzinga
  3. Morning Market Gainers

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. Pharmacological Advancements in Neuroscience Drug Discovery & ...

    Benzinga
  6. Orexigen Soars On Obesity Drug's Surprise Health Boon

    IBD
  7. Morning Market Losers

    Benzinga
  8. Benzinga's Top #PreMarket Losers

    Benzinga
  9. 10 Stocks You Should Be Watching Today

    Benzinga
  10. Arena Pharmaceuticals Misses Q4 Expectations

    Benzinga
  11. Earnings Scheduled For March 2, 2015

    Benzinga
  12. CNBC's Stock Pops & Drops From January 21

    Benzinga
  13. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  14. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  15. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  16. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  17. Morning Market Losers

    Benzinga
  18. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  19. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  20. Benzinga's Top #PreMarket Losers

    Benzinga
  21. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  22. 5 Obesity Stocks Investors Are Watching

    Benzinga
  23. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  24. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  25. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  26. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  27. Morning Market Gainers

    Benzinga
  28. Benzinga's Top #PreMarket Gainers

    Benzinga
  29. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  30. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  31. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  32. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  33. Benzinga's Top #PreMarket Gainers

    Benzinga
  34. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  35. Earnings Scheduled For November 3, 2014

    Benzinga
  36. 3 Pharma Companies Fighting Obesity

    Benzinga
  37. Benzinga's Top #PreMarket Gainers

    Benzinga
  38. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  39. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  40. Earnings Scheduled For August 1, 2014

    Benzinga
  41. Benzinga's Top #PreMarket Losers

    Benzinga
  42. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  43. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  44. Benzinga's Top #PreMarket Losers

    Benzinga
  45. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  46. FDA delays Orexigen drug

    IBD
  47. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  48. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  49. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  50. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  51. Earnings Scheduled For May 12, 2014

    Benzinga
  52. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  53. Benzinga's Top #PreMarket Losers

    Benzinga
  54. Earnings Scheduled For February 27, 2014

    Benzinga
  55. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  56. Top Trending Tickers On StockTwits For February 14

    Benzinga
  57. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  58. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  59. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  60. The Top Five Drug Launches Of 2013

    IBD
  61. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  62. Benzinga's Top #PreMarket Gainers

    Benzinga
  63. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  64. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  65. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  66. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  67. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  68. Benzinga's Top #PreMarket Losers

    Benzinga
  69. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  70. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  71. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  72. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  73. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  74. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  75. Benzinga's Top Pre-Market Losers

    Benzinga
  76. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  77. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  78. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  79. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  80. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  81. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  82. Stocks Hitting 52-Week Lows

    Benzinga
  83. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  84. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  85. Stocks Hitting 52-Week Lows

    Benzinga
  86. Stocks Hitting 52-Week Lows

    Benzinga
  87. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  88. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  89. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  90. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  91. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  92. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  93. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  94. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  95. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  96. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  97. Vivus fell 4.2% to 13.72

    IBD
  98. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  99. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  100. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!